{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T13:22:57Z","timestamp":1726492977582},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,17]]},"DOI":"10.7759\/cureus.22311","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T08:32:43Z","timestamp":1645086763000},"source":"Crossref","is-referenced-by-count":1,"title":["Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine"],"prefix":"10.7759","author":[{"given":"DJ  L","family":"Infimate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Yumnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh S","family":"Galagali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Kabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Kaeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Psoriasiform disorders","author":"Gudjonsson JE","year":"2019","unstructured":"Gudjonsson JE, Elder JT. Psoriasiform disorders. Fitzpatrick\u2019s Dermatology. Kang S, Amagai M, Bruckner AL, et al. (ed): McGraw Hill Education, New York, NY; 2019. 457-97."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/258430","article-title":"Possible triggering effect of influenza vaccination on psoriasis","volume":"2015","author":"Gunes AT","year":"2015","unstructured":"Gunes AT, Fetil E, Akarsu S, Ozbagcivan O, Babayeva L. Possible triggering effect of influenza vaccination on psoriasis. J Immunol Res. 2015, 2015:258430. 10.1155\/2015\/258430","journal-title":"J Immunol Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella R","year":"2021","unstructured":"Ella R, Reddy S, Blackwelder W, et al.. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021, 398:2173-84. 10.1016\/S0140-6736(21)02000-6","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.067","article-title":"Widespread psoriasis flare following influenza vaccination","volume":"35","author":"Shi CR","year":"2017","unstructured":"Shi CR, Nambudiri VE. Widespread psoriasis flare following influenza vaccination. Vaccine. 2017, 35:4785-6. 10.1016\/j.vaccine.2017.06.067","journal-title":"Vaccine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2013.25.4.489","article-title":"New onset guttate psoriasis following pandemic H1N1 influenza vaccination","volume":"25","author":"Shin MS","year":"2013","unstructured":"Shin MS, Kim SJ, Kim SH, Kwak YG, Park HJ. New onset guttate psoriasis following pandemic H1N1 influenza vaccination. Ann Dermatol. 2013, 25:489-92. 10.5021\/ad.2013.25.4.489","journal-title":"Ann Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19882","article-title":"COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision","volume":"185","author":"Sotiriou E","year":"2021","unstructured":"Sotiriou E, Bakirtzi K, Papadimitriou I, Paschou E, Vakirlis E, Lallas A, Ioannides D. COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision. Br J Dermatol. 2021, 185:209-10. 10.1111\/bjd.19882","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17449","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski PK","year":"2021","unstructured":"Krajewski PK, Matusiak \u0141, Szepietowski JC. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021, 35:e632-4. 10.1111\/jdv.17449","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.34172\/hpp.2021.32","article-title":"A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report","volume":"11","author":"Onsun N","year":"2021","unstructured":"Onsun N, Kaya G, I\u015f\u0131k BG, G\u00fcne\u015f B. A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report. Health Promot Perspect. 2021, 11:261-2. 10.34172\/hpp.2021.32","journal-title":"Health Promot Perspect"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17582","article-title":"Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre","volume":"35","author":"Sotiriou E","year":"2021","unstructured":"Sotiriou E, Tsentemeidou A, Bakirtzi K, Lallas A, Ioannides D, Vakirlis E. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2021, 35:e857-9. 10.1111\/jdv.17582","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n997","article-title":"What do we know about India's Covaxin vaccine?","volume":"373","author":"Thiagarajan K","year":"2021","unstructured":"Thiagarajan K. What do we know about India's Covaxin vaccine?. BMJ. 2021, 373:n997. 10.1136\/bmj.n997","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15007","article-title":"Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine","volume":"46","author":"Yoneyama S","year":"2019","unstructured":"Yoneyama S, Kamiya K, Kishimoto M, Komine M, Ohtsuki M. Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine. J Dermatol. 2019, 46:e442-3. 10.1111\/1346-8138.15007","journal-title":"J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2018.11.001","article-title":"Impact of yellow fever vaccine on patients with psoriasis: preliminary results","volume":"94","author":"de Barros MH","year":"2019","unstructured":"de Barros MH, Avelleira JC, Mendes KA. Impact of yellow fever vaccine on patients with psoriasis: preliminary results. An Bras Dermatol. 2019, 94:757-9. 10.1016\/j.abd.2018.11.001","journal-title":"An Bras Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2012.03.001","article-title":"New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin","volume":"30","author":"Hung CT","year":"2012","unstructured":"Hung CT, Wang WM, Tsao CW, Chiang CP. New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin. Dermatol Sin. 2012, 30:108-11. 10.1016\/j.dsi.2012.03.001","journal-title":"Dermatol Sin"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2\u2014advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand JM","year":"2021","unstructured":"Gelfand JM, Armstrong AW, Bell S, et al.. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2\u2014advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021, 84:1254-68. 10.1016\/j.jaad.2020.12.058","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-021-00349-0","article-title":"Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS-Cov-2 vaccination strategies?","volume":"21","author":"Speeckaert R","year":"2021","unstructured":"Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van Geel N. Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS-Cov-2 vaccination strategies?. Drugs R D. 2021, 21:341-50. 10.1007\/s40268-021-00349-0","journal-title":"Drugs R D"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","volume":"51","author":"Sellaturay P","year":"2021","unstructured":"Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021, 51:861-3. 10.1111\/cea.13874","journal-title":"Clin Exp Allergy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84168-psoriasis-flare-up-after-covaxin-bbv152-whole-virion-inactivated-vaccine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:05Z","timestamp":1707507965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84168-psoriasis-flare-up-after-covaxin-bbv152-whole-virion-inactivated-vaccine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.22311","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}